[1] Gordon S. Alternative activation of macrophages[J].Nat Rev Immunol, 2003, 3(1): 23-35.[2] Hao NB,Lu MH,Fan YH, et al. Macrophages in tumor microenvironments and the progression of tumors[J]. Clin Dev Immunol, 2012, 2012:948098.[3] Cassetta L, Cassol E, Poli G. Macrophage polarization in health and disease[J]. Scientific World J, 2011, 11:2391-2402.[4] Chávez-Galán L, Olleros ML, Vesin D, et al. Much more than M1 and M2 macrophages, there are also CD169(+) and TCR(+) macrophages[J]. Front Immunol,2015, 6:263.[5] Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance[J]. Trends Immunol, 2009, 30(10): 475-487.[6] Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties[J]. Immunity, 2003, 19(1): 71-82.[7] Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins[J]. Science, 1994, 264(5164): 1415-1421.[8] Park C, Li S, Cha E, et al. Immune response in Stat2 knockout mice[J]. Immunity, 2000, 13(6): 795-804.[9] Brombacher F, Arendse B, Peterson R, et al. Analyzing classical and alternative macrophage activation in macrophage/neutrophil-specific IL-4 receptor-alpha-deficient mice[J]. Methods Mol Biol, 2009: 531:225-252.[10] Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective[J]. Annu Rev Immunol, 2009, 27: 451-483.[11] Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance[J]. Annu Rev physiol, 2010, 72: 219-246.[12] Pascual G, Fong AL, Ogawa S, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma[J]. Nature, 2005, 437(7059): 759-763.[13] Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. Macrophage-specific PPARγ controls alternative activation and improves insulin resistance[J].Nature, 2007,447(7148):1116-1120 .[14] Szanto A, Balint BL, Nagy ZS, et al. STAT6 transcription factor is a facilitator of the nuclear receptor PPARγ-regulated gene expression in macrophages and dendritic cells[J]. Immunity, 2010, 33(5): 699-712.[15] El Kasmi KC, Qualls JE, Pesce JT, et al. Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens[J]. Nat Immunol, 2008, 9(12): 1399-1406.[16] Hu HM, Baer M, Williams SC, et al. Redundancy of C/EBP, and in supporting the lipopolysaccharideinduced transcription of IL-6 and monocyte chemoattractant 1[J]. J Immunol, 1998,160(5): 2334-2342 .[17] Kim C,Wilcox-Adelman S,Sano Y, et al. Anti-inflammatory cAMP signaling and cell migration genes coopted by the anthrax bacillus[J]. Proc Natl Acad Sci USA, 2008, 105(16):6150-6155.[18] Marigo I, Bosio E, Solito S, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPβ transcription factor[J]. Immunity, 2010, 32(6): 790-802.[19] Savitsky D, Tamura T, Yanai H, et al. Regulation of immunity and oncogenesis by the IRF transcription factor family[J]. Cancer Immunol Immunother, 2010, 59(4): 489-510.[20] De Santa F, Totaro MG, Prosperini E, et al. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing[J]. Cell, 2007, 130(6): 1083-1094.[21] Van der Valk P, De Groot CJ. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS[J]. Neuropathol Appl Neurobiol, 2000, 26(1): 2-10.[22] Rawji KS, Yong VW. The benefits and detriments of macrophages/microglia in models of multiple sclerosis[J]. Clin Dev Immunol, 2013, 2013:948976.[23] Hughes JE, Srinivasan S, Lynch KR, et al. Sphingosine-1-phosphate induces an anti- inflammatory phenotype in macrophages[J]. Circ Res, 2008, 102(8): 950-958.[24] Kopadze T, Dehmel T, Hartung HP, et al. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis[J]. Arch Neurol, 2006, 63(11): 1572-1578.[25] Jung S, Siglienti I, Grauer O, et al. Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate[J]. J Neuroimmunol, 2004, 148(1): 63-73.[26] Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet?[J]. Science, 2013, 339(6117): 286-291.[27] Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy [J]. Immunity, 2014, 41(1): 49-61.[28] Yang XD, Ai W, Asfaha S, et al. Histamine deficiency promotes inflammation-associated carcinogenesis through reduced myeloid maturation and accumulation of CD11b+ Ly6G+ immature myeloid cells[J]. Nat Med, 2011, 17(1): 87-95.[29] Cohen NA, Zeng S, Kim TS, et al. Angiogenesis inhibition augments the effect of imatinib in gastrointestinal stromal tumor[J]. J Am Coll Surgeons, 2013, 217(3): S140.[30] Monini P, Colombini S, Stürzl M, et al. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma[J]. Blood, 1999, 93(12): 4044-4058.[31] Escamilla J, Schokrpur S, Liu C, et al. CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy[J]. Cancer Res, 2015, 75(6): 950-962.[32] Duluc D, Corvaisier M, Blanchard S, et al. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages[J]. Int J Cancer, 2009, 125(2): 367-373.[33] Rolny C, Mazzone M, Tugues S, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF[J]. Cancer Cell, 2011, 19(1): 31-44.[34] Apter AJ. Advances in adult asthma diagnosis and treatment in 2013[J]. J Allergy Clin Immunol, 2014, 133(1): 49-56.[35] Careau E, Bissonnette EY. Adoptive transfer of alveolar macrophages abrogates bronchial hyperresponsiveness[J]. Am J Resp Cell Mol, 2004, 31(1): 22-27.[36] Alexis NE, Soukup J, Nierkens S, et al. Association between airway hyperreactivity and bronchial macrophage dysfunction in individuals with mild asthma[J]. Am J Physiol-Lung C, 2001, 280(2): L369-L375.[37] Moreira AP, Cavassani KA, Hullinger R, et al. Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease[J]. J Allergy Clin Immunol, 2010, 126(4): 712-721,e7. |